Oseltamivir Phosphate eq.to Oseltamivir

Description

PharmAlliance International Labs: Pioneering Antiviral Solutions

Introduction:

Welcome to PharmAlliance International Labs, your beacon of pharmaceutical excellence dedicated to transforming global healthcare. With an unwavering commitment to innovation and patient-centricity, we are thrilled to introduce our latest breakthrough: Oseltamivir Phosphate. As advocates for optimal health outcomes, we strive to provide effective solutions that empower individuals worldwide in their journey towards wellness.

Product Description:

• Product Name: Oseltamivir Phosphate (equivalent to Oseltamivir)
• Drug Classification: Antiviral Agent
• Strength: 75 mg
• Product Form: Tablets
• Packing Specifications: 10’s

Pharmacokinetics:

Oseltamivir boasts rapid absorption from the gastrointestinal tract upon oral administration, undergoing extensive conversion to its active metabolite, oseltamivir carboxylate, by hepatic esterases. With an impressive bioavailability of approximately 80%, oseltamivir carboxylate demonstrates dose-proportional pharmacokinetics, achieving peak plasma concentrations within 3-4 hours. Its favorable elimination half-life of 6-10 hours permits convenient twice-daily dosing regimens.

Pharmacodynamics:

Harnessing its antiviral prowess, Oseltamivir intervenes in the influenza virus life cycle by inhibiting the neuraminidase enzyme, a pivotal player in viral replication. By curtailing the release of newly formed virus particles from infected cells, Oseltamivir mitigates symptom severity and shortens the duration of influenza illness, offering much-needed relief to sufferers.

Formulations:

Available in tablet form, each Oseltamivir Phosphate tablet contains 75 mg of oseltamivir phosphate, ensuring precise dosing and consistent therapeutic efficacy.

Indications:

Oseltamivir Phosphate stands as a frontline defense against influenza virus infection in adults and pediatric patients aged 2 weeks and older. Effective against both influenza A and B strains, including those resistant to alternative antiviral therapies, its versatile utility extends to treatment and prophylaxis alike.

Usage:

For influenza treatment, Oseltamivir Phosphate should be promptly initiated within 48 hours of symptom onset, with adults and adolescents aged 13 years and older receiving 75 mg orally twice daily for 5 days. In prophylactic settings, a once-daily regimen is recommended for the duration specified by healthcare providers

Dosage:

Tailored dosing of Oseltamivir Phosphate accounts for variations in age and weight, with precise instructions provided by healthcare professionals or product labeling.

Side Effects:

While generally well-tolerated, Oseltamivir Phosphate may elicit mild and transient adverse effects such as nausea, vomiting, headache, and diarrhea. Rare occurrences of allergic reactions or neuropsychiatric events necessitate prompt medical evaluation.

At PharmAlliance International Labs, our commitment to pharmaceutical excellence knows no bounds. Trust in Oseltamivir Phosphate and embark on a journey towards enhanced well-being. For inquiries or assistance, consult your healthcare provider or explore our website for comprehensive resources and support.